ai4gi Logo

satisfaihealth

Satisfai Health is pleased to announce a partnership with the International Bowel Ultrasound (IBUS) Group e.V. to develop Artificial Intelligence (AI) solutions for intestinal ultrasound (IUS) in patients with Inflammatory Bowel Disease (IBD), namely Crohn’s disease and Ulcerative Colitis.

The annual MICCAI conference attracts the world’s leading biomedical scientists, engineers, and clinicians from a wide range of disciplines associated with medical imaging and computer assisted intervention. The conference series includes three days of scientific content, including oral presentations and poster sessions. Workshops, tutorials, and challenges are held on the days preceding and succeeding the conference.

Satisfai Health is pleased to have Dr. Michael Byrne deliver the keynote speech at the workshop Cancer Prevention through early detection (CaPTion). 

 

Date: Sept 18 – 22, 2022, Singapore

The future of GI practice will include artificial intelligence (AI) – from diagnosis to treatment to streamlining your business processes. AI in healthcare will increase opportunities to improve patient outcomes, reduce costs, and impact population health. While AI technology in GI is relatively new, AI will soon transform GI practice. 

On May 20, join us for a hands-on workshop that was designed for physicians and other healthcare professionals, fellows, and administrators.   Satisfai Health is pleased to have Dr. Michael Byrne, CEO, present his thoughts on “AI and Endoscopy Training:  Good or Bad?”. 

 

Date: May 20, 2022, San Diego, CA

Satisfai Health is pleased to participate in the Portsmouth Advanced Endoscopy face to face symposium.  This event will bring participants the latest developments in endoscopy.

During the event, Dr. Michael Byrne, Satisfai Health CEO, will provide his insights on Artificial Intelligence in Colonoscopy. 

Moderators: Prof Helmut Neumann, Prof Colin Rees, Prof James East 

Speakers

  • Prof Cesare Hassan – Detection
  • Dr Yuichi Mori – Characterisation
  • Dr Michael Byrne – Beyond detection & characterisation
 

Date: May 9 – 10, 2022, Portsmouth, UK

Satisfai Health appreciates being invited to attend the recent GHIN World Conference where Dr. Michael Byrne, CEO, participated in their Artificial Intelligence in Healthcare session with other panelists Judy Barkal and Darren Gates.

 

Date: March 24 & 25, 2022 – Virtual – 8:00 AM to 5:00 PM PST

Satisfai Heath was pleased to have Dr. Michael Byrne attend BC Cancer’s Colonoscopy multi-disciplinary session focusing on adenoma detection rate (ADR) organized by Dr. Jennifer Telford. Dr. Byrne spoke on ADR from an Artificial Intelligence perspective.

Satisfai Health thanks Dr. Telford and other notable speakers for the chance to help others learn more about this important clinical KPI. 

 

Date: March 10, 2022 – Virtual – 6:00 to 8:00 PM PST

Satisfai was pleased to have our CEO, Dr. Michael Byrne, present at Endoscopy on Air in a session on “AI, Advanced Imaging, and Digital Pathology”.

Satisfai thanks Endoscopy on Air for making this informative session possible. 

 

Date: February 8, 2022 – Virtual

Satisfai Health has signed an engagement letter appointing Fort Capital Partners as a Financial Advisor to the Company.  This appointment is in connection with the Company’s recent launch of its Series A private placement offering of common stock, the proceeds from which will be used to complete certain strategic technology acquisitions and continue to fund the build out of Satisfai’s Health’s AI team to deliver on the Company’s mission to become the global leader in providing AI solutions in Gastroenterology and GI Endoscopy.

Satisfai was pleased to have Dr. Michael Byrne presenting at the World Investors & Entrepreneurs Summit (WISE) 2022 hosted virtually and in person in San Francisco, California.   

By all accounts, the summit was a resounding success and Satisfai thanks Dr. Prasun Mishra for providing us with this excellent opportunity to share our story.  WISE really supported their aim to be come the world’s biggest gathering of investors and entrepreneurs.

WISE 2022 brought together a global ecosystem of investors (angels, family offices, venture capital, private equity) and successful entrepreneurs to create new opportunities, partnerships, collaboration, acquisition, and investment.

Date: January 8 – 13, 2022 – San Francisco, CA

Satisfai was pleased to have Dr. Michael Byrne join the international faculty for this event held by the endo-update organizers in collaboration with the ESGE.  

Satisfai thanks all for this opportunity. 

 

 

Date: November 25 – 27

Categories

Request a Demo

Dr. Reno Panaccione

Director of IBD

Dr. Panaccione is currently a Professor of Medicine, the Director of the Inflammatory Bowel Disease Clinic at the University of Calgary and Director of Gastroenterology Research.

Dr. Panaccione graduated from the University of Western Ontario (London, Ontario) with a degree in Medicine in 1993. He went on to complete his Internal Medicine and Gastroenterology training at the University of Western Ontario and is certified as a fellow of the Royal College of Physicians and Surgeons of Canada in both Internal Medicine and Gastroenterology. Dr. Panaccione completed advanced training in Inflammatory Bowel Disease at the Mayo Clinic in Rochester, Minnesota. He joined the faculty of Medicine at the University of Calgary in 1999. He is an internationally recognized expert in inflammatory bowel disease. He has lectured nationally and internationally on various topics in inflammatory bowel disease and has delivered over 200 lectures in the last five years.

He is the author of many peer-reviewed articles (~250) and book chapters (25) on inflammatory bowel disease. His special interest lies in the fields of advanced therapies, biological therapy, and delivery of care through the implementation of clinical trials. He is a recognized authority on the use of biologics and has co-authored numerous guidelines on the management of inflammatory bowel disease for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn’s disease and ulcerative colitis. He has published in and reviews for prestigious journals including NEJM, Lancet, Gastroenterology and Gut. He sits on the editorial board of Inflammatory Bowel Diseases, JCC, APT, and the Canadian Journal of Gastroenterology.

He is presently the medical director for the Crohn’s and Colitis Canada (CCC) Calgary Chapter and sits on the Medical Advisory council for the Crohn’s and Colitis Foundation of Canada. He is the national chair of the CCC scholarship program. He has been awarded the highest honour, the Finkelstein award by Crohn’s and Colitis Canada for his work in the field of IBD. He is also an elected member of the International Organization of Inflammatory Bowel Disease (IOIBD) reflecting his status in the area. He was awarded the CAG Visiting Professor Award in 2016 for his contribution o the field of Gastroenterology in Canada. He is ranked amongst the top ten experts in the field worldwide (www.expertscape.com). He presently holds a senior leadership position within Alberta Health Services as the Medical Lead for Systems Integration with the mandate of improving the efficiency and quality of care that is delivered to patients.

Dr. Douglas Rex

Director of Colorectal Cancer

Dr. Douglas K. Rex is Distinguished Professor of Medicine at Indiana University School of Medicine, Chancellor’s Professor at Indiana University Purdue University Indianapolis, and Director of Endoscopy at Indiana University Hospital in Indianapolis. He graduated from Harvard College, Summa Cum Laude in 1976 and with highest distinction from Indiana University School of Medicine in 1980. He served as Chief Medical Resident at Indiana University Hospital and joined the faculty at Indiana University in 1985. He received the Outstanding Teacher Award in the Introduction to Medicine course five times and has been awarded the Indiana University School of Medicine Outstanding Teacher Award as well as Department of Medicine’s Excellence in Teaching Award. He is a full-time clinical gastroenterologist at Indiana University Hospital.

His major research interests have been in colorectal disease and, in particular, colorectal cancer screening and the technical performance of colonoscopy. He co-authored the colorectal cancer screening recommendations of the American College of Gastroenterology and the U.S. Multi-Society Task Force on Colorectal Cancer. He also authored the recommendations on quality in colonoscopy of the U.S. Multi-Society Task Force on Colorectal Cancer and the American College of Gastroenterology/American Society of Gastrointestinal Endoscopy. He has authored more than 200 original research papers, 55 book chapters, 200 invited papers, 40 editorials, and 40 guideline papers. He is an Associate Editor of Journal Watch Gastroenterology and serves on the editorial boards of 11 gastroenterology journals.

He is the current chair of the U.S. Multi-Society (ACG, ASGE, AGA, ACP-ASIM) Task Force on Colorectal Cancer. He has also served in the American College of Gastroenterology as Chairman of the Board of Governors and is a Past President of the ACG. He is a member of the Governing Board of ASGE and a recipient of the Rudolph V. Schindler Award from ASGE.

Dr. Michael Byrne

CEO & Founder

Dr. Michael Byrne provides senior leadership and clinical expertise to Satisfai Health and is a clinical innovator with over 20 years experience as a practicing physician. He is the founder of both Satisfai Health and its ai4gi joint venture. He is a Clinical Professor of Medicine in the Division of Gastroenterology at Vancouver General Hospital and UBC. He is also director of the Interventional Endoscopy Fellowship at VGH, and is the former Director of Endoscopy at VGH/UBC.

He has worked in the medical device space for several years. Prior to his role with Satisfai Health and his participation in the ai4gi project, he has worked with the Biotechnology Industry in several areas including colon cancer genetic testing, and novel applications of Photodynamic therapy for Gastrointestinal disease.

He is a graduate of Cambridge and Liverpool Universities. He has a strong research background in both basic science and clinical medicine with hands-on training in molecular sciene and pharmacology. He received an MD by thesis from the University of Cambridge for his work on Helicobacter Pylori and Cyclooxygenase. He also has a long track record of clinical research. Dr. Byrne has published extensively with over 90 peer reviewed publications and over 100 abstract presentations at National and International Meetings.

After several years working in the UK and Ireland, Dr. Byrne completed an Interventional Endoscopy Fellowship as well as working as an attending physician at Duke University Medical Center, North Carolina. He moved to his current role in Vancouver in 2003.

His main clinical interests are in the field of ERCP, interventional endoscopy, optical biopsy, colon cancer, pancreaticobiliary disease, and IBD.